High-throughput screens for small-molecule inhibitors of Pseudomonas aeruginosa biofilm development.
Pseudomonas aeruginosa is both a model biofilm-forming organism and an opportunistic pathogen responsible for chronic lung infections in cystic fibrosis (CF) patients and infections in burn patients, among other maladies. Here we describe the development of an efficient high-throughput screen to identify small-molecule modulators of biofilm formation. This screen has been run with 66,095 compounds to identify those that prevent biofilm formation without affecting planktonic bacterial growth. The screen is a luminescence-based attachment assay that has been validated with several strains of P. aeruginosa and compared to a well-established but low-throughput crystal violet staining biofilm assay. P. aeruginosa strain PAO1 was selected for use in the screen both because it forms robust biofilms and because genetic information and tools are available for the organism. The attachment-inhibited mutant, strain PAO1 DeltafliC, was used as a screening-positive control. We have also developed and validated a complementary biofilm detachment assay that can be used as an alternative primary screen or secondary screen for the attachment screening-positive compounds. We have determined the potencies of 61 compounds against biofilm attachment and have identified 30 compounds that fall into different structural classes as biofilm attachment inhibitors with 50% effective concentrations of less than 20 microM. These small-molecule inhibitors could lead to the identification of their relevant biofilm targets or potential therapeutics for P. aeruginosa infections.
Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA.
Lauren M
LM
Junker
Jon
J
Clardy
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001287:Attachment Sites, Microbiological / Q000187:drug effects; D018441:Biofilms / Q000187:drug effects*; D003470:Culture Media; D003625:Data Collection; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical / Q000379:methods; D049449:Luminescence; D011550:Pseudomonas aeruginosa / Q000187:drug effects*; D015203:Reproducibility of Results; D013329:Structure-Activity Relationship
D000900:Anti-Bacterial Agents; D003470:Culture Media